SOLIGENIX, INC. Repayments of Convertible Debt
SOLIGENIX, INC. (SNGX) reported Repayments of Convertible Debt of $1.37 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-08-07
- SOLIGENIX, INC. repayments of convertible debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- SOLIGENIX, INC. repayments of convertible debt for the quarter ending 2025-09-30 was $0.00.
- SOLIGENIX, INC. repayments of convertible debt for the quarter ending 2025-06-30 was $0.00.
- SOLIGENIX, INC. repayments of convertible debt for the quarter ending 2025-03-31 was $1.37M.
- SOLIGENIX, INC. repayments of convertible debt for fiscal 2025 was $1.37M, a 0.00% increase from fiscal 2024.
- SOLIGENIX, INC. repayments of convertible debt for fiscal 2024 was $1.37M, a 80.39% decline from fiscal 2023.
- SOLIGENIX, INC. repayments of convertible debt for fiscal 2023 was $7.00M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-08-07 | $1.37M 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2026-08-07 | $1.37M 10-Q · filed 2025-11-07 | $2.06M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.37M 10-Q · filed 2026-08-07 | $2.06M derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-03-31 | $1.37M 10-Q · filed 2026-05-08 | $2.06M derived: sum of 2 quarters · filed 2026-05-08 | ||
| 2024-12-31 | $686.44K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.37M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $686.44K 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $0.00 derived: sum of 2 quarters · filed 2025-03-21 | $6.00M derived: sum of 3 quarters · filed 2025-03-21 | $7.00M 10-K · filed 2025-03-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $6.00M derived: sum of 2 quarters · filed 2024-11-08 | $7.00M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $7.00M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $1.00M 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |